Cargando…

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease

The current study evaluated amyloid-β oligomers (Aβo) in cerebrospinal fluid as a clinical biomarker for Alzheimer’s disease (AD). We developed a highly sensitive Aβo ELISA using the same N-terminal monoclonal antibody (82E1) for capture and detection. CSF samples from patients with AD, mild cogniti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hölttä, Mikko, Hansson, Oskar, Andreasson, Ulf, Hertze, Joakim, Minthon, Lennart, Nägga, Katarina, Andreasen, Niels, Zetterberg, Henrik, Blennow, Kaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682966/ https://www.ncbi.nlm.nih.gov/pubmed/23799095 http://dx.doi.org/10.1371/journal.pone.0066381

Ejemplares similares

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
por: Hertze, Joakim, et al.
Publicado: (2014)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
por: van Westen, Danielle, et al.
Publicado: (2016)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
por: Janelidze, Shorena, et al.
Publicado: (2017)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
por: Schultz, Nina, et al.
Publicado: (2019)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
por: Wennström, Malin, et al.
Publicado: (2015)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease
por: Hertze, Joakim, et al.
Publicado: (2013)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease
por: Andersson, Carl-Henrik, et al.
Publicado: (2016)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid
por: Meda, Francisco J., et al.
Publicado: (2023)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
por: Voevodskaya, Olga, et al.
Publicado: (2016)

Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later
por: Nägga, Katarina, et al.
Publicado: (2018)

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
por: Portelius, Erik, et al.
Publicado: (2010)

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
por: Johansson, Per, et al.
Publicado: (2013)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein
por: Zettergren, Anna, et al.
Publicado: (2019)

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
por: Lautner, Ronald, et al.
Publicado: (2017)

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid
por: Frankel, Rebecca, et al.
Publicado: (2019)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
por: Bremell, Daniel, et al.
Publicado: (2013)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
por: Gao, Carol Man, et al.
Publicado: (2010)

Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients
por: Lukkarinen, Heikki, et al.
Publicado: (2022)

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
por: Selnes, Per, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2djig01k1d1ehfa4r0kcr1ssf9